ERBB2 and breast carcinoma: We demonstrated that CHD4 silencing inhibits tumor growth in vivo and proliferation in vitro by strongly reducing cell cycle progression in xenografts of MCF10DCIS.com cells, in transgenic, HER2-activated, mouse model and in patient-derived xenografts (PDX) of breast cancer.